Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The impact of eculizumab on routine complement assays

20 Jun 2018

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood groups and transfusion
Share to Complement system in diseases
Share to Platelet Disorders and Treatments

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 29935209
DOI: 10.1016/j.jim.2018.06.010

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The impact of eculizumab on routine complement assaysPMID 29935209Read ↗

Expanding Horizons in Complement Analysis and Quality ControlSemantic proximity Read ↗

Complement testing in the clinical laboratorySemantic proximity Read ↗

Developments in anti-complement therapy; from disease to clinical trialSemantic proximity Read ↗

First approval of a complement C3 inhibitor opens up autoimmune and inflammatory opportunitiesSemantic proximity Read ↗

Diagnosis of complement alternative pathway disordersSemantic proximity Read ↗

Complement C5 inhibition in patients with COVID-19 - a promising target?Semantic proximity Read ↗

Analysis of the Complement System in the Clinical Immunology LaboratorySemantic proximity Read ↗

Clinical promise of next-generation complement therapeuticsSemantic proximity Read ↗

Post-partum atypical haemolytic-uraemic syndrome treated with eculizumab: terminal complement activity assessment in clinical practiceSemantic proximity Read ↗

Eculizumab for atypical haemolytic uraemic syndrome: what next?Semantic proximity Read ↗

With complements: C3 inhibition in the clinicSemantic proximity Read ↗

Complement Inhibition with the C5 Blocker LFG316 in Severe COVID-19Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.